Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.

Similar presentations


Presentation on theme: "The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis."— Presentation transcript:

1 The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis. L. Brent Mitchell, Jean L. Rouleau, Gary E. Newton, Jonathon Howlett, Elizabeth Yetisir, George A. Wells, Anthony S.L. Tang

2 DECLARATION - 1 Beta-Blockers ACE-I / ARB Aldo Block CRT Declaration of Potential Conflict of Interest I have nothing to declare

3 BACKGROUND - 1 Beta-Blockers ACE-I / ARB Aldo Block ICD CRT CHF - Proven Effective Therapies on All-Cause Mortality

4 multicenter, randomized, two parallel-group, clinical trial 1798 patients with NYHA II/III congestive heart failure receiving optimal medical therapy with LVEF ≤ 0.30 and QRSd ≥ 120ms (≥ 200ms if V-paced) and with an independent indication for an ICD were randomized 1:1 to receive an ICD or a CRT-ICD Resynchronization-defibrillation for Ambulatory heart Failure Trial (RAFT) BACKGROUND - 2

5 RAFT Results: Death or CHF Hospitalization BACKGROUND Cumulative Incidence Years of Follow-up 5 60 ICD CRT-ICD HR = % CI: 0.64 – 0.87 p < Tang AS et al. N Engl J Med 363: , 2010

6 BACKGROUND - 4 CHF - Proven Effective Therapies on All-Cause Mortality Beta-Blockers ACE-I / ARB Aldo Block ICD CRT

7 PURPOSE To assess the contemporary importance, independence, and dose-dependence of beta-blocker therapy in the congestive heart failure patients studied in RAFT.

8 METHODS PATIENT POPULATION: RAFT patients that were treated with one of bisoprolol, carvedilol, or metoprolol. BETA-BLOCKER TARGET DOSAGES: were as defined by ESC guidelines 1 - bisoprolol 10 mg/d, carvedilol 50 mg/d, metoprolol 200 mg/d. PRIMARY OUTCOME: death or CHF hospitalization. STATISTICS: Times to outcome displayed as KM curves. Sixteen variables were included in stepwise proportional hazards analyses. 1. McMurray JJV et al. Eur Heart J 33: , 2012

9 RESULTS - 1 The RAFT Patient Population: N = 1798, mean age 66 yrs, 83% male, 67% ischemic 80% NYHA Class II, mean LVEF % beta-blocker use, 97% ACE-I / ARB use 42% spironolactone use This Substudy Patient Population (82%): N = 1474, mean age 66 yrs, 83% male, 66% ischemic 82% NYHA Class II, mean LVEF % beta-blocker use, 97% ACE-I / ARB use 42% spironolactone use

10 RESULTS - 2 Beta-Blocker Use Distributions < 50% target ≥ 50% target number (39%) (34%) (67%) p < 0.001

11 Population Differences by Beta-Blocker Dosage RESULTS - 3 VARIABLEBB < 50% TargetBB ≥ 50% TargetP-value Age (years ± SD)67.5 ± ± 9.6< Ischemic HD n(%)541 (73.2%)436 (59.3%)< NYHA Class II n(%)568 (76.9%)621 (84.5%) Weight (kg ± SD)79.6 ± ± 18.1< BMI (± SD)27.1 ± ± 5.4< Prior CABG n(%)288 (39.0%)214 (29.1%)< PVD n(%)88 (11.9%)61 (8.3%) CHF Hosp < 6mo n(%)211 (28.6%)166 (22.6%) Beta-blocker use at baseline n(%)643 (87.0%)709 (96.3%)< ASA use n(%)517 (70.0%)477 (64.9%) Warfarin use n(%)231 (31.3%)266 (36.2%) Clopidogrel use n(%)130 (17.6 %)96 (13.1%) Amiodarone use n(%)114 (15.4%)78 (10.6%) eGFR (ml/min/1.73m 2 ± SD)58.7 ± ± MWT distance (m ± SD)346 ± ±

12 Death / CHF Hospitalization by Beta-Blocker Dosage RESULTS Cumulative Incidence Years of Follow-up 5 60 < 50% ≥ 50% HR = % CI = 1.24 – 1.81 p < 0.001

13 Independent Predictors of Primary Outcome RESULTS - 5 PARAMETERHR (95% CI)P-value previous CABG1.63 ( )< beta-blocker < 50% target1.50 ( )< ICD without CRT1.50 ( )< ischemic heart disease1.39 ( )0.01 peripheral vascular disease1.36 ( )0.02 lower estimated GFR (per 5 units)1.10 ( )0.0002

14 RESULTS - 6 Death / CHF Hospitalization by Beta-Blocker Dosage Years of Follow-up < 50% ≥ 50% Incidence Incidence by beta-blocker dosage (N=1474) Years of Follow-up < 50% ≥ 50% by carvedilol dosage (N=629) by bisoprolol dosage (N=489) by metoprolol dosage (N=356) p < p = 0.006

15 RESULTS - 7 Cumulative Incidence Years of Follow-up Death / CHF Hospitalization by RAFT Randomisation Randomised to CRT-ICD (N=740) Years of Follow-up p < p = 0.07 Randomised to ICD (N=734) < 50% ≥ 50% < 50% ≥ 50%

16 independent predictors of death / CHF hospitalization were: beta-blockers use at < 50% (not ≥ 50%) of target dosage use of an ICD (not a CRT-ICD) ischemic heart disease and previous CABG peripheral vascular disease or impaired renal function with lower dosage these outcome were 50% more likely there were no efficacy differences among the beta-blockers carvedilol is more often used at ≥ 50% of target dosages the superiority of higher beta-blocker dosages are less evident in CRT-ICD patients than in ICD patients INFERENCES In this subgroup analysis of CHF patients studied in RAFT:

17 The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis. L. Brent Mitchell, Jean L. Rouleau, Gary E. Newton, Jonathon Howlett, Elizabeth Yetisir, George A. Wells, Anthony S.L. Tang


Download ppt "The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis."

Similar presentations


Ads by Google